Products - Skin cancer | Topic | NICE

Showing 5 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 April 2021
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
19 December 2024
Lifileucel for previously treated unresectable or metastatic melanoma ID3863
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC